Objective. Gel aspiration-ejection (GAE) has recently been developed for the rapid production of dense, anisotropic collagen gel scaffolds with adjustable collagen fibrillar densities. In this study, a GAE system was applied to produce aligned Schwann cells within a type-1 collagen matrix to generate GAE-engineered neural tissues (GAE-EngNT) for potential nerve tissue engineering applications. Approach. The stability and mechanical properties of the constructs were investigated along with the viability, morphology and distribution of Schwann cells. Having established the methodology to construct stable robust Schwann cell-loaded engineered neural tissues using GAE (GAE-EngNTs), the potential of these constructs in supporting and guiding neuronal regeneration, was assessed both in vitro and in vivo. Main results. Dynamic mechanical analysis strain and frequency sweeps revealed that the GAE-EngNT produced via cannula gauge number 16 G (∼1.2 mm diameter) exhibited similar linear viscoelastic behaviors to rat sciatic nerves. The viability and alignment of seeded Schwann cells in GAE-EngNT were maintained over time post GAE, supporting and guiding neuronal growth in vitro with an optimal cell density of 2.0 × 106 cells ml−1. An in vivo test of the GAE-EngNTs implanted within silicone conduits to bridge a 10 mm gap in rat sciatic nerves for 4 weeks revealed that the constructs significantly promoted axonal regeneration and vascularization across the gap, as compared with the empty conduits although less effective regeneration compared with the autograft groups. Significance. Therefore, this is a promising approach for generating anisotropic and robust engineered tissue which can be used with Schwann cells for peripheral nerve repair.
The increasing number of elderly people across the globe has led to a rise in osteoporosis and bone fractures, significantly impacting the quality of life and posing substantial health and economic burdens. Despite the development of tissue-engineered bone constructs and stem cell-based therapies to address these challenges, their efficacy is compromised by inadequate vascularization and innervation during bone repair. Innervation plays a pivotal role in tissue regeneration, including bone repair, and various techniques have been developed to fabricate innervated bone scaffolds for clinical use. Incorporating neural-related cells and delivering neurotrophic factors are emerging strategies to accelerate bone regeneration through innervation. However, research into neurogenic cell sources remains limited. Meanwhile, neural stem/progenitor cells (NSPCs) are emerging as promising cells for treating neurodegenerative disorders and spinal cord injuries due to their multifunctional capacity in promoting angiogenesis, neurogenesis, and immunomodulation, making them promising candidates for achieving innervation in bone substitutes. In this review, we discuss the regenerative potential of NSPCs in tissue regeneration. We propose their feasibility for bone therapy through their secreted exosomes during traumatic brain injury, contributing to the acceleration of bone healing. Additionally, we discuss the essential neurotrophic factors released from NSPCs and their osteogenic properties. This review emphasizes the necessity for further investigation of the role of NSPCs in bone regeneration.
Non-small cell lung cancer (NSCLC), the most common subtype of lung cancer, remains a major contributor to cancer-related mortality worldwide. Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, has beenrepurposed as an anticancer agent for NSCLC therapy. In the present study, celecoxib-loaded Soluplus/zein composite nanoparticles coated with chitosan were successfully developed and evaluated as a promising pulmonary drug delivery system for NSCLC. The nanoparticles were prepared using an antisolvent precipitation technique and demonstrated favorable physicochemical properties. The optimized formulation exhibited a particle size of approximately 190 nm with high encapsulation efficiency (85.34%), and high drug-loading capacity (14.21%). The chitosan coating increased the zeta potential to nearly +30.42 mV, yielding enhanced stability and desirable mucoadhesive properties for pulmonary administration. In vitro release studies revealed sustained release under simulated physiological lung conditions, following diffusion- and swelling-controlled release mechanisms. Cytotoxicity evaluation using the MTT assay demonstrated significant anticancer activity against A549 lung cancer cells while maintaining good biocompatibility toward BEAS-2B normal human bronchial epithelial cells. The optimized nanoparticles also showed efficient transport across an air–liquid interface (ALI) airway epithelial barrier, with a Papp value of 4.15 × 10–4 cm·s–1 and 0.38% translocation after 24 h. Furthermore, aerosolized nanoparticles displayed excellent aerodynamic performance, with a fine particle fraction (FPF) of 68.51% and a mass median aerodynamic diameter (MMAD) of 3.93 μm using the Next Generation Impactor (NGI). Overall, these findings highlight the potential of celecoxib-loaded Soluplus/zein nanoparticles coated with chitosan as a promising pulmonary drug delivery system for NSCLC via nebulization.